haemophilia
Novo Nordisk presents promising findings for haemophilia treatment
June 23, 2025Medical Communications, Research and Development Haematology, International Society on Thrombosis and Haemostasis Congres, Novo Nordisk, clinical trial data, haemophilia, market approval
Novo Nordisk has presented data indicating that a direct switch to Mim8 (denecimig) prophylaxis treatment from emicizumab without a need …
Qfitlia approved by FDA to treat haemophilia A or B
March 31, 2025Research and Development FDA, Haematology, Sanofi, haemophilia, pharma
The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran) as the first therapy in the US to treat …
First patients treated with HEMGENIX® (etranacogene dezaparvovec) gene therapy for haemophilia B in Denmark
January 21, 2025Sales and Marketing CSL, Denmark, genetic, haemophilia, treatment
21 January 2025 – Copenhagen, Denmark – CSL Behring Denmark today announced that the first Danish patients with haemophilia B …
Results from Sanofi’s ALTUVIIIO XTEND-Kids phase 3 trial published in NEJM
July 22, 2024Research and Development Altuviiio, Haematology, Sanofi, haemophilia
Sanofi has announced that full results from the XTEND-Kids phase 3 study were published in The New England Journal of …
Pfizer’s Beqvez approved by FDA for haemophilia B treatment
April 29, 2024Medical Communications FDA, Haematology, Pfizer, haemophilia
Pfizer has announced that the US Food and Drug Administration (FDA) has approved Beqvez (fidanacogene elaparvovec-dzkt) for the treatment of …
FDA approves BioMarin’s Roctavian for adults with severe haemophilia A
June 30, 2023Medical Communications BioMarin, FDA, Haematology, Roctavian, haemophilia
Global biotechnology company BioMarin Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has approved Roctavian (valoctocogene roxaparvocec-rvox) …
uniQure announces sale of royalty interest in Hemgenix for up to $400m
May 16, 2023Sales and Marketing Haematology, Hemgenix, haemophilia, royalties, uniQure
uniQure has announced that it has entered a definitive agreement to sell a portion of the royalty rights due to …
US approval for haemophilia drug derived from genetically engineered rabbit’s milk
April 2, 2020Sales and Marketing FDA, US, haemophilia, pharma
The FDA has announced the approval of Sevenfact, a haemophilia therapy the active ingredient from which is expressed in genetically …
Novo Nordisk halts three haemophilia studies after participants suffer thrombotic events
March 17, 2020Manufacturing and Production, Research and Development Novo Nordisk, haemophilia, pharma
Novo Nordisk has moved to temporarily shut down two of its Phase 3 and one of its Phase 2 clinical …
NHS Scotland gives green light to funding haemophilia A drug Hemlibra
December 18, 2019Research and Development NHS, haemophilia, haemophilia B, haemophilia a, nhs scotland
NHS Scotland has commissioned Hemlibra (emicizumab), by Chungai Pharma UK Ltd and Roche Products Ltd, to treat people with congenital …
Irish haemophilia A patients to get continued access to Sobi’s extended half-life factor replacement therapy
December 17, 2019Manufacturing and Production haemophilia, haemophilia B, haemophilia a
The Republic of Ireland’s Haemophilia Product Selection and Monitoring Advisory Board (HPSMAB) and Sobi United Kingdom and Republic of Ireland, …
NHS England to fund Hemlibra for patients with severe haemophilia
August 21, 2019Research and Development Chugai, Hemlibra, Roche, haemophilia, pharma
NHS England is to fund Roche and Chugai Pharma UK’s haemophilia drug Hemlibra, for people with sever congenital haemophilia A …
Roche unveils wave of strong Hemlibra data in haemophilia A with or without factor VIII inhibitors
July 9, 2019Manufacturing and Production, Research and Development Roche, haemophilia, pharma
Roche revealed a swathe of new data on Hemlibra (emicizumab) at the International Society on Thrombosis and Haemostasis (ISTH) 2019 …
Pfizer and Sangamo’s haemophilia A gene therapy shows promise at Phase 1/2
July 8, 2019Research and Development, Sales and Marketing Pfizer, Sangamo, haemophilia, pharma
Pfizer and Sangamo Therapeutics have shared new Phase 1/2 data for their investigational SB-525 gene therapy in the treatment of …
European approval for Novo’s Esperoct in haemophilia A
June 21, 2019Medical Communications, Sales and Marketing Esperoct, Novo Nordisk, haemophilia, pharma
The European Commission has awarded approval to Novo Nordisk’s extended half-life factor VIII therapy Esperoct (turoctocog alfa pegol, N8-GP) for …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
